Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive Stage Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Trilaciclib (Primary) ; Carboplatin; Etoposide
Indications Small cell lung cancer
Focus Adverse reactions; Registrational
Sponsors G1 Therapeutics

07 Jun 2022 Results of pooled analysis from the G1T28-05 and G1T28-02 trials presented at the 58th Annual Meeting of the American Society of Clinical Oncology
07 Jun 2022 Results of post-hoc analysis data pooled from G1T28-05 and G1T28-02 trials published in the Simcere Pharmaceutical Group Media Release.
02 Jun 2022 Results from a post-hoc analysis of (NCT02499770 , NCT03041311 , NCT02514447 ) were presented in a poster at the 2022 American Society of Clinical Oncology (ASCO) annual meeting

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com